Overall, the COVID-19 global health crisis changed the way organizations operate. Businesses have needed to be more agile in order to comply with social distancing and work-at-home mandates. Essentially, companies were forced to rely more on technology to keep their business operating — much of this scenario will likely become the new normal.
In the pharmaceutical industry, manufacturers have been tasked with revising their operations and processes to function effectively in this new paradigm. If the day-to-day efforts of maintaining productivity, supply chains, and release schedules while scaling the hurdles of changing regulatory guidelines aren’t daunting enough, these tasks are even more challenging when stakeholders are dispersed across several locations. That said, pharma manufacturing organizations are making
modernization a higher priority. In this paper we detail the approaches pharma companies are taking to ensure long-term relevance in the value chain.